NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Total BS per normal, NWBO's OS data was better than expected, IMPO.

It was certainly far worse than most all longs here expected. It was even lower than my estimate based on the 2018 SNO data (16-20%).

SNO had the blended 5Y OS at 16%. Most longs estimated that the number for the 233 DCvax-L arm would be around 25%.

Also, many were certain that the 233 treatment arm would easily show an improvement over the 99 placebo arm.

Maybe we can review all those estimated K/M charts by Radio and others that showed how they expected far better OS.